PembrolizumabGrade 2 arthralgia and development of acquired drug resistance: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2020年 / 1818卷 / 1期

关键词：

D O I：

10.1007/s40278-020-82506-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：226 / 226

相关论文

共 50 条

[1] Icotinib/pembrolizumabGrade 3 immune-related dermatitis and drug resistance: case report
Reactions Weekly, 2022, 1924 (1) : 245 - 245
[2] GefitinibDiarrhoea and acquired drug resistance: case report
Reactions Weekly, 2018, 1731 (1) : 124 - 124
[3] PembrolizumabGrade 2 subclinical hypothyroidism: case report
Reactions Weekly, 2024, 2037 (1) : 349 - 349
[4] PembrolizumabGrade 2 colitis and Hepatitis: case report
Reactions Weekly, 2025, 2051 (1) : 261 - 261
[5] AntineoplasticsNo response and acquired drug resistance: case report
Reactions Weekly, 2023, 1953 (1) : 57 - 57
[6] AntineoplasticsLack of drug effect and acquired resistance: case report
Reactions Weekly, 2022, 1888 (1) : 51 - 51
[7] AntineoplasticsLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2023, 1944 (1) : 83 - 83
[8] AntineoplasticsLack of efficacy and acquired drug resistance : case report
Reactions Weekly, 2024, 2018 (1) : 57 - 57
[9] Sintilimab/sorafenibRash and acquired drug resistance: case report
Reactions Weekly, 2022, 1926 (1) : 427 - 427
[10] AntineoplasticsLack of efficacy and acquired drug resistance: case report
Reactions Weekly, 2022, 1921 (1) : 36 - 36

← 1 2 3 4 5 →